AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

finance.yahoo.com · 2026-08-29

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

TickrTrends take: AbbVie operates in a competitive healthcare landscape where direct comparisons to peers like Eli Lilly are common among investors seeking relative value. Given TickrTrends' assessment that ABBV is fairly valued, investors focused on valuation metrics should monitor whether the company's pipeline progression, revenue growth, and margin trends maintain ABBV's current fair value positioning relative to its healthcare sector competitors. Relative valuation analysis between comparable healthcare companies can help identify whether ABBV offers better or worse risk-adjusted returns at its current price levels compared to alternatives in the sector.

Read the full story at finance.yahoo.com →